Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174448Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chaccour, Carlos | - |
| dc.contributor.author | Ruiz Castillo, Paula | - |
| dc.contributor.author | Richardson, Mary-Ann | - |
| dc.contributor.author | Moncunill, Gemma | - |
| dc.contributor.author | Casellas, Aina | - |
| dc.contributor.author | Carmona Torre, Francisco | - |
| dc.contributor.author | Giráldez, Miriam | - |
| dc.contributor.author | Schwartz Mota, Juana | - |
| dc.contributor.author | Yuste, José R. | - |
| dc.contributor.author | Azanza, José Ramón | - |
| dc.contributor.author | Fernández, Miriam | - |
| dc.contributor.author | Reina, Gabriel | - |
| dc.contributor.author | Dobaño, Carlota, 1969- | - |
| dc.contributor.author | Brew, Joe | - |
| dc.contributor.author | Sadaba, Belen | - |
| dc.contributor.author | Hammann, Felix | - |
| dc.contributor.author | Rabinovich, Regina | - |
| dc.date.accessioned | 2021-03-01T07:28:48Z | - |
| dc.date.available | 2021-03-01T07:28:48Z | - |
| dc.date.issued | 2020-06-08 | - |
| dc.identifier.issn | 1745-6215 | - |
| dc.identifier.uri | http://hdl.handle.net/2445/174448 | - |
| dc.description.abstract | Objectives: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7 post-treatment. | - |
| dc.format.extent | 4 p. | - |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | eng | - |
| dc.publisher | BioMed Central | - |
| dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.1186/s13063-020-04421-z | - |
| dc.relation.ispartof | Trials, 2020, vol. 21 | - |
| dc.relation.uri | http://dx.doi.org/10.1186/s13063-020-04421-z | - |
| dc.rights | cc by (c) Chaccour et al., 2020 | - |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
| dc.source | Articles publicats en revistes (ISGlobal) | - |
| dc.subject.classification | SARS-CoV-2 | - |
| dc.subject.classification | Medicaments antivírics | - |
| dc.subject.other | SARS-CoV-2 | - |
| dc.subject.other | Antiviral agents | - |
| dc.title | The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/publishedVersion | - |
| dc.date.updated | 2021-02-26T19:00:57Z | - |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
| dc.identifier.pmid | 32513289 | - |
| Appears in Collections: | Articles publicats en revistes (ISGlobal) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Chaccour_C_Trials_2020.pdf | 444.54 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
